EnvudeucitinibEnvudeucitinib is an investigational new drug that is being evaluated for the treatment of psoriasis. It is a selective tyrosine kinase 2 (TYK2) inhibitor developed by Fronthera U.S. Pharmaceuticals LLC and now owned by Alumis, Inc. for the treatment of autoimmune diseases. Read from the Drugbox of the Wikipedia article Envudeucitinib, revision 1330275762.

Property

Value

Formula

C22H18[2H]6N6O3, 426.51 g/mol

The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.